Immunotherapy with checkpoint inhibitors is now considered standard first-line treatment in patients with metastatic melanoma, but there are still a range of factors to consider before choosing the therapeutic strategy for these patients. In this podcast, Doctor Damien Kee from Austin Health speaks to Associate Professor Phil Parente, Director of Cancer Services at Eastern Health, ...
Treatment choices in BRAF mutant and wild-type metastatic melanoma
3 Nov 2020
Sponsored by Bristol Myers Squibb Australia Pty Ltd